- Avicanna´s (AVCN) completes first commercial export of Aureus™ branded THC active pharmaceutical ingredients to Chile
- SMGH has successfully completed the export of 20.75 kilograms of high THC and high CBD full spectrum psychoactive cannabis resin
- SMGH to cultivate up to 1,720 cannabis plants to produce seeds from four of SMGH’s registered genetics
- Avicanna is an established leader in cannabinoid research and development
- Avicanna Inc. (AVCN) is in the grey and is trading at C$1.08 12:02 pm ET
Avicanna´s Colombian Subsidiary has completed its first commercial export of Aureus™ banded THC active pharmaceutical ingredients to Chile.
Santa Marta Golden Hemp S.A.S. has also been granted a quota by the Colombian government to cultivate and process up to 10,267 kg of dry flower to manufacture psychoactive (THC) crude and standardized extracts and final phyto-therapeutic pharmaceutical products.
SMGH has successfully completed the export of 20.75 kilograms of high THC and high CBD full spectrum psychoactive cannabis resin to a leading Chilean homeopathic and naturopathic pharmaceutical company.
SMGH has been granted a cultivation manufacturing quota by the Colombian government, permitting the company to process up to 10,267 kg of dry flower from its registered and optimized genetics to produce psychoactive derivatives.
This substantial sum will be collectively utilized to export crude and standardized extracts and finished phyto-therapeutic pharmaceutical forms.
The quotas also allow SMGH to cultivate up to 1,720 cannabis plants to produce seeds from four of SMGH’s registered genetics.
These seeds can be utilized to supply other licensed companies either inside Colombia or foreign markets that permit the import, commercialization, and cultivation of cannabis.
This positions Avicanna to be a supplier of THC-containing active pharmaceutical ingredients and finished products for medical purposes to several markets worldwide that are welcoming such imports.
The Cannabis Extracts will be utilized to manufacture cannabinoid-based pharmaceutical products, which are currently in the final stages of clinical development and registration before being commercialized in South America.
The Cannabis Extracts branded as Aureus™ are cultivated, extracted, and manufactured by SMGH.
SMGH also supplies pharmaceutical and cosmetics companies with cannabinoids, including CBD, THC, and rare cannabinoids such as CBG, and supplies global cultivation companies with standardized and feminized seeds.
Lucas Nosiglia, President of Avicanna LATAM, commented: “We continue to set the standards, pioneer and establish our footprint in South America across our different business units.”
“We are pleased to see legislation and opportunities related to cannabinoids-based cosmetics, medical and pharmaceutical products evolve at a rapid rate and believe we are in a great position to fortify our leadership position in the region,” added Nosiglia.
Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on developing and commercializing plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.
Avicanna is an established leader in cannabinoid research and development.
It primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada, and collaborates with leading Canadian academic and medical institutions.
Avicanna Inc. (AVCN) is in the grey and is trading at C$1.08 12:02 pm ET.